medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-11-48-52medsovet-1914Research ArticleБРОНХОПУЛЬМОНОЛОГИЯ, ЛОРBRONCHOPULMONOLOGY, ENTКАК ДОЛГО ЛЕЧИТЬ ПАЦИЕНТОВ С ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИЕЙ? В ФОКУСЕ — КОРОТКИЕ КУРСЫ АНТИМИКРОБНОЙ ТЕРАПИИHOW LONG SHOULD THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA CONTINUE? FOCUS ON SHORT-COURSE ANTIMICROBIAL THERAPYЗайцевА. А.ZaitsevA. A.

Доктор медицинских наук.

Москва

MD.

Moscow

МакаревичА. М.MakarevichA. M.

Кандидат медицинских наук.

Хабаровск

PhD in medicine.

Khabarovsk

Главный военный клинический госпиталь им. академика Н.Н. Бурденко Минздрава РоссииРоссияBurdenko General Military Clinical Hospital, MoH RFRussian Federation301-й Военный клинический госпиталь Минздрава РоссииРоссия301st Military Clinical Hospital of the Ministry of Health of RussiaRussian Federation2017030720170114852Copyright © Зайцев А.А., Макаревич А.М., 20172017Зайцев А.А., Макаревич А.М.Zaitsev A.A., Makarevich A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1914

До настоящего времени дискуссия, касающаяся длительности антибактериальной терапии при внебольничной пневмонии (ВП), продолжается.  В ряде клинических рекомендаций схемы длительности приема антибиотика разнятся. Между тем появляется  все больше данных, свидетельствующих, что краткосрочные  режимы антибиотикотерапии  при нетяжелых респираторных инфекциях нижних дыхательных путей являются привлекательными и перспективными.

Till today, the duration of antibiotic therapy for community-acquired pneumonia (EP) remains a subject of debate. In different clinical guidelines  the  duration of antibiotic administration varies. Meanwhile, there is growing evidence  that short-term antibiotic regimens for non-severe respiratory infections of the lower respiratory tract seem attractive and promising.

внебольничная пневмонияантимикробная терапиядлительность курсаcommunity-acquired pneumoniaantimicrobial therapycourse durationReferencesMandell L, Richard G et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Доступно на: http://www.thoracic.org/sections/publications/statements/pages/mtpi/idsaatscap.html.Mandell L, Richard G et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Доступно на: http://www.thoracic.org/sections/publications/statements/pages/mtpi/idsaatscap.html.Mandell LA, Marrie TJ, Grossman RF et al, the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis., 2000, 31: 383-421.Mandell LA, Marrie TJ, Grossman RF et al, the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis., 2000, 31: 383-421.Lim WS, Baudouin SV, George RC et al. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults – update 2009. Thorax, 2009, 64(Suppl III): iii1-55.Lim WS, Baudouin SV, George RC et al. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults – update 2009. Thorax, 2009, 64(Suppl III): iii1-55.Woodhead M, Blasi F, Ewig S et al. New guidelines for the management of adult lover respiratory tract infections. Clin Microbiol Infect, 2011, 17(6): 1-59.Woodhead M, Blasi F, Ewig S et al. New guidelines for the management of adult lover respiratory tract infections. Clin Microbiol Infect, 2011, 17(6): 1-59.Чучалин А.Г. с соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М., 2010. 82 с.Чучалин А.Г. с соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М., 2010. 82 с.Овчинников Ю.В., Зайцев А.А., Синопальников А.И. с соавт. Диагностика, лечение и вакцинопрофилактика внебольничной пневмонии у военнослужащих. Методические указания по лечению внебольничной пневмонии у военнослужащих. ГВКГ имени Н.Н. Бурденко. М., 2015, c. 81.Овчинников Ю.В., Зайцев А.А., Синопальников А.И. с соавт. Диагностика, лечение и вакцинопрофилактика внебольничной пневмонии у военнослужащих. Методические указания по лечению внебольничной пневмонии у военнослужащих. ГВКГ имени Н.Н. Бурденко. М., 2015, c. 81.Рачина С.А., Козлов Р.С., Шаль Е.П. и др. Анализ антибактериальной терапии госпитализированных пациентов с внебольничной пневмонией в различных регионах РФ: уроки многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. антимикроб. химиотер., 2009, 11(1): 66-78.Рачина С.А., Козлов Р.С., Шаль Е.П. и др. Анализ антибактериальной терапии госпитализированных пациентов с внебольничной пневмонией в различных регионах РФ: уроки многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. антимикроб. химиотер., 2009, 11(1): 66-78.Aliberti S et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J, 2010, 36: 128-134.Aliberti S et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J, 2010, 36: 128-134.Li J, Winston L, Moore D, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med, 2007, 120(9): 783-90.Li J, Winston L, Moore D, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med, 2007, 120(9): 783-90.Dimopoulos G, Matthaiou D, Karageorgopoulos D et al. Shortversus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs, 2008, 68(13): 1841-54.Dimopoulos G, Matthaiou D, Karageorgopoulos D et al. Shortversus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs, 2008, 68(13): 1841-54.Dunbar L, Wunderink R, Habib M et al. Highdose, short-course levofloxacin for communityacquired pneumonia: a new treatment paradigm. Clin Infect Dis, 2003, 37(6): 752-60.Dunbar L, Wunderink R, Habib M et al. Highdose, short-course levofloxacin for communityacquired pneumonia: a new treatment paradigm. Clin Infect Dis, 2003, 37(6): 752-60.Scalera N, File T. How long should we treat community-acquired pneumonia? Curr Opin Infect Dis, 2007, 20(2): 177-81.Scalera N, File T. How long should we treat community-acquired pneumonia? Curr Opin Infect Dis, 2007, 20(2): 177-81.Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. Antimicrob Chemother, 2002, 49: 897-903.Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. Antimicrob Chemother, 2002, 49: 897-903.Ушкалова Е.А. Короткие курсы антибиотикотерапии при инфекциях дыхательных путей. Фарматека, 2007, 3/4(82). Доступно на: http://www.pharmateca.ru.Ушкалова Е.А. Короткие курсы антибиотикотерапии при инфекциях дыхательных путей. Фарматека, 2007, 3/4(82). Доступно на: http://www.pharmateca.ru.Синопальников А.И., Зайцев А.А. Снижение стоимости антибактериальной терапии: от общих вопросов к анализу стратегий. Российские Медицинские Вести, 2008, 3(13): 34-42.Синопальников А.И., Зайцев А.А. Снижение стоимости антибактериальной терапии: от общих вопросов к анализу стратегий. Российские Медицинские Вести, 2008, 3(13): 34-42.Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of b-lactam: risk factors for carrige of penicillin-resistant Streptococcus pneumoniae. JAMA, 1998, 279: 365-70.Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of b-lactam: risk factors for carrige of penicillin-resistant Streptococcus pneumoniae. JAMA, 1998, 279: 365-70.Schrag S, Pena C, Fernandez J et al. Effect of short-course high-dose amoxicillin therapy on resistant pneumococcal carriage. JAMA, 2001, 286: 49-56.Schrag S, Pena C, Fernandez J et al. Effect of short-course high-dose amoxicillin therapy on resistant pneumococcal carriage. JAMA, 2001, 286: 49-56.Morris D, De Souza A, Jones JA, Morgan W. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. European Journal of Clinical Microbiology and Infectious, 1991, 10: 859-861.Morris D, De Souza A, Jones JA, Morgan W. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. European Journal of Clinical Microbiology and Infectious, 1991, 10: 859-861.Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol, 1979, 73: 235-240.Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol, 1979, 73: 235-240.Clinical efficacy of three days versus five days of oral amoxicillin for the treatment of childhood pneumonia: a multicentre double-blind trial. MASCOT group. Lancet, 2002, 360: 835-841.Clinical efficacy of three days versus five days of oral amoxicillin for the treatment of childhood pneumonia: a multicentre double-blind trial. MASCOT group. Lancet, 2002, 360: 835-841.Three days versus five days treatment with amoxicillin for nonsevere pneumonia in young children: a multicentre randomized controlled trial. ISCAP study group. BMJ, 2004, 328: 791-794.Three days versus five days treatment with amoxicillin for nonsevere pneumonia in young children: a multicentre randomized controlled trial. ISCAP study group. BMJ, 2004, 328: 791-794.Лютина Е.И., Малаховский Ю.Е., Манеров Ф.К. Новые подходы к антибактериальной терапии внебольничной неосложненной пневмонии у детей. Педиатрия, 1996, 6: 89-91.Лютина Е.И., Малаховский Ю.Е., Манеров Ф.К. Новые подходы к антибактериальной терапии внебольничной неосложненной пневмонии у детей. Педиатрия, 1996, 6: 89-91.Léophonte P, Choutet P, Gaillat J et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses, 2002, 32(7): 369-381.Léophonte P, Choutet P, Gaillat J et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses, 2002, 32(7): 369-381.Dunbar L, Khashab M, Kahn J et al. Efficacy of 750mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin., 2004, 20(4): 555-563.Dunbar L, Khashab M, Kahn J et al. Efficacy of 750mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin., 2004, 20(4): 555-563.Shorr A, Khashab M, Xiang J et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized community-acquired pneumonia Fine Risk Class III/IV community-acquired pneumonia patients. Respir. Med., 2006, 100(12): 2129-2136.Shorr A, Khashab M, Xiang J et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized community-acquired pneumonia Fine Risk Class III/IV community-acquired pneumonia patients. Respir. Med., 2006, 100(12): 2129-2136.Shorr A, Zadeikis N, Xiang J et al. A multicenter, randomized, double-blind, retrospective comparison of 5and 10-day regimens of levofloxacin in a subgroup of patients aged ≥ 65 years with community-acquired pneumonia. Clin. Ther., 2005, 27(8): 1251-1259.Shorr A, Zadeikis N, Xiang J et al. A multicenter, randomized, double-blind, retrospective comparison of 5and 10-day regimens of levofloxacin in a subgroup of patients aged ≥ 65 years with community-acquired pneumonia. Clin. Ther., 2005, 27(8): 1251-1259.http://www.fda.gov.http://www.fda.gov.Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs, 2003, 63: 2169-84.Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs, 2003, 63: 2169-84.File T, Milkovich G, Tennenberg A et al. Clinical implications of 750 mg, 5-days levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin, 2004, 20: 9: 1473-1481.File T, Milkovich G, Tennenberg A et al. Clinical implications of 750 mg, 5-days levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin, 2004, 20: 9: 1473-1481.Noreddin A, Elkhatib W, Cunnion К, Zhanel G. Cumulative clinical experience from over a decade of use of levofloxacinin communityacquired pneumonia: critical appraisal and role in therapy. Drug, Healthcare and Patient Safety, 2011, 3: 59-68.Noreddin A, Elkhatib W, Cunnion К, Zhanel G. Cumulative clinical experience from over a decade of use of levofloxacinin communityacquired pneumonia: critical appraisal and role in therapy. Drug, Healthcare and Patient Safety, 2011, 3: 59-68.Anderson V, Perry C. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 2008, 68(4): 535-65.Anderson V, Perry C. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 2008, 68(4): 535-65.Torres A, Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert Opin Pharmacother, 2012, 13(8): 1203-12.Torres A, Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert Opin Pharmacother, 2012, 13(8): 1203-12.Zanel G, Noreddin A.M. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol, 2001, 1: 459-463.Zanel G, Noreddin A.M. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol, 2001, 1: 459-463.Chien S, Wrong F, Flower C et al. Double-blind evaluation of safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers. Ibid, 1998, 42: 885-888.Chien S, Wrong F, Flower C et al. Double-blind evaluation of safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers. Ibid, 1998, 42: 885-888.Fish D, Chow A. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet, 1997, 32: 101-119.Fish D, Chow A. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet, 1997, 32: 101-119.Nightingale C. Appropriate use of antimicrobials: pharmacodynamic principles. J Respir Dis, 1999, 20(10): 13-18.Nightingale C. Appropriate use of antimicrobials: pharmacodynamic principles. J Respir Dis, 1999, 20(10): 13-18.Зайцев А.А., Макаревич А.М. Короткие курсы левофлоксацина в терапии внебольничной пневмонии. Дыхание & Пульмонология и отоларингология, 2013, 1: 1-4.Зайцев А.А., Макаревич А.М. Короткие курсы левофлоксацина в терапии внебольничной пневмонии. Дыхание & Пульмонология и отоларингология, 2013, 1: 1-4.Norredin A, Marras T, Sanders K et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg, and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents, 2004, 24: 5: 479-484.Norredin A, Marras T, Sanders K et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg, and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents, 2004, 24: 5: 479-484.Khashab M, Xiang J, Kahn J. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin, 2006, 22(10): 1997-2006.Khashab M, Xiang J, Kahn J. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin, 2006, 22(10): 1997-2006.Доступно на: http://www.antibiotic.ru/index.php?article=2111.Доступно на: http://www.antibiotic.ru/index.php?article=2111.

The authors declare that there are no conflicts of interest present.